ImmuCell
ICCC
12 hedge funds and large institutions have $1.55M invested in ImmuCell in 2015 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and closing their positions.
23% more capital invested
Capital invested by funds: $1.25M → $1.55M (+$294K)
0% more funds holding
Funds holding: 12 → 12 (0)
0.39% less ownership
Funds ownership: 8.49% → 8.1% (-0.39%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$15.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$51.1K |
| 2 |
Morgan Stanley
New York
|
-$32.2K |
| 3 |
SRC
Shufro Rose & Co
New York
|
-$12.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$839 |
ICCC Hedge Fund Activity: Q1 2015 in Review
12 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q1 2015, worth a combined $1.55M — up 23% from $1.25M a quarter earlier.
Fund positioning in ICCC was balanced in Q1 2015: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $15.1K. The largest seller was Shepherd Kaplan Krochuk, cutting an estimated $51.1K.
- 12 institutional investors held ImmuCell (ICCC) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $1.55M of ImmuCell stock for Q1 2015, up 23% quarter-over-quarter.
- 0 funds opened new ImmuCell positions in Q1 2015 and 0 closed out.
- The largest ImmuCell buyer in Q1 2015 was Renaissance Technologies, an estimated $15.1K added.
- The largest ImmuCell seller in Q1 2015 was Shepherd Kaplan Krochuk, an estimated $51.1K sold.
Based on aggregated 13F filings for Q1 2015.